| NCT04420533 |
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms |
https://ClinicalTrials.gov/show/NCT04420533 |
Recruiting |
Chang Gung Memorial Hospital |
2022-05-31 |
| NCT04016324 |
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study |
https://ClinicalTrials.gov/show/NCT04016324 |
Recruiting |
MedtronicNeuro |
2020-08-01 |
| NCT03371342 |
Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03371342 |
Completed |
Medy-Tox |
2018-05-31 |
| NCT03320850 |
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT03320850 |
Active, not recruiting |
Allergan |
2020-06-26 |
| NCT03251300 |
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing |
https://ClinicalTrials.gov/show/NCT03251300 |
Recruiting |
Far Eastern Memorial Hospital |
2020-12-31 |
| NCT03194425 |
Standardization of Lead Placement for Sacral Neuromodulation. Part 1 |
https://ClinicalTrials.gov/show/NCT03194425 |
Active, not recruiting |
Universiteit Antwerpen |
2022-08-31 |
| NCT03175029 |
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT03175029 |
Active, not recruiting |
Taiho Pharmaceutical Co., Ltd. |
2020-12-31 |
| NCT03168828 |
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury |
https://ClinicalTrials.gov/show/NCT03168828 |
Completed |
Taris Biomedical LLC |
2018-07-26 |
| NCT03149809 |
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease |
https://ClinicalTrials.gov/show/NCT03149809 |
Recruiting |
VA Office of Research and Development |
2021-08-31 |
| NCT03109379 |
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03109379 |
Completed |
Taris Biomedical LLC |
2019-09-27 |
| NCT03106623 |
Study of ONO-8577 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03106623 |
Completed |
Ono Pharmaceutical Co. Ltd |
2017-08-29 |
| NCT03104101 |
Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females |
https://ClinicalTrials.gov/show/NCT03104101 |
Completed |
Alexandria University |
2015-11-30 |
| NCT03059134 |
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan |
https://ClinicalTrials.gov/show/NCT03059134 |
Completed |
Buddhist Tzu Chi General Hospital |
2016-04-27 |
| NCT03052764 |
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT03052764 |
Completed |
Allergan |
2018-12-10 |
| NCT03023241 |
Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis |
https://ClinicalTrials.gov/show/NCT03023241 |
Recruiting |
Cantonal Hospital, Frauenfeld |
2019-12-31 |
| NCT03017170 |
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB |
https://ClinicalTrials.gov/show/NCT03017170 |
Completed |
Weill Medical College of Cornell University |
2018-07-31 |
| NCT02992509 |
IVES for Treatment of UUI and OAB |
https://ClinicalTrials.gov/show/NCT02992509 |
Completed |
Loma Linda University |
2015-11-30 |
| NCT02940314 |
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT02940314 |
Completed |
Hanmi Pharmaceutical Company Limited |
2016-05-31 |
| NCT02938507 |
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects |
https://ClinicalTrials.gov/show/NCT02938507 |
Completed |
Velicept Therapeutics, Inc. |
2016-12-31 |
| NCT02916693 |
Mirabegron For Erectile Dysfunction |
https://ClinicalTrials.gov/show/NCT02916693 |
Completed |
Johns Hopkins University |
2020-01-01 |
| NCT02849418 |
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT02849418 |
Completed |
GlaxoSmithKline |
2018-03-02 |
| NCT02835846 |
Investigation of the Effect of the Female Urinary Microbiome on Incontinence |
https://ClinicalTrials.gov/show/NCT02835846 |
Completed |
Loyola University |
2018-03-31 |
| NCT02820844 |
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02820844 |
Completed |
GlaxoSmithKline |
2018-03-06 |
| NCT02790307 |
Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome |
https://ClinicalTrials.gov/show/NCT02790307 |
Completed |
University College, London |
2013-09-30 |
| NCT02757768 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) |
https://ClinicalTrials.gov/show/NCT02757768 |
Completed |
Astellas Pharma Inc |
2018-08-14 |
| NCT02751931 |
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT02751931 |
Completed |
Astellas Pharma Inc |
2018-11-05 |
| NCT02742389 |
Urodynamic Testing: Can we Improve Patient Experience? |
https://ClinicalTrials.gov/show/NCT02742389 |
Completed |
Boston Urogynecology Associates |
2017-06-30 |
| NCT02735499 |
Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT02735499 |
Completed |
The Hospital of Vestfold |
2016-10-31 |
| NCT02723279 |
Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women |
https://ClinicalTrials.gov/show/NCT02723279 |
Completed |
Shanghai Institute of Acupuncture, Moxibustion and Meridian |
2016-10-31 |
| NCT02715024 |
Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT02715024 |
Completed |
Astellas Pharma Inc |
2011-04-30 |
| NCT02701010 |
Behavioural Therapy Program for Female Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02701010 |
Completed |
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi |
2013-04-30 |
| NCT02677753 |
Percutaneous Nerve Evaluation With Fluoroscopy Versus Without |
https://ClinicalTrials.gov/show/NCT02677753 |
Completed |
University of Louisville |
2019-04-30 |
| NCT02670486 |
Audiovisual Stimulus During Urodynamics |
https://ClinicalTrials.gov/show/NCT02670486 |
Completed |
Women and Infants Hospital of Rhode Island |
2016-05-31 |
| NCT02667470 |
Reproducibility Study of OABSS and Its Response to Treatment |
https://ClinicalTrials.gov/show/NCT02667470 |
Completed |
Astellas Pharma Inc |
2013-05-31 |
| NCT02657057 |
Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB |
https://ClinicalTrials.gov/show/NCT02657057 |
Completed |
Instituto Médico Tecnológico SL |
2017-02-28 |
| NCT02656173 |
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH) |
https://ClinicalTrials.gov/show/NCT02656173 |
Completed |
Astellas Pharma Inc |
2017-07-21 |
| NCT02620410 |
Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System |
https://ClinicalTrials.gov/show/NCT02620410 |
Active, not recruiting |
Axonics Modulation Technologies, Inc. |
2017-06-30 |
| NCT02614482 |
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. |
https://ClinicalTrials.gov/show/NCT02614482 |
Completed |
CHU de Quebec-Universite Laval |
2018-06-30 |
| NCT02601287 |
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients |
https://ClinicalTrials.gov/show/NCT02601287 |
Completed |
Allergan |
2016-07-31 |
| NCT02600715 |
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository |
https://ClinicalTrials.gov/show/NCT02600715 |
Completed |
University of Kansas Medical Center |
2017-06-26 |
| NCT02568774 |
Acupuncture on Post-Stroke Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02568774 |
Completed |
The University of Hong Kong |
2018-08-31 |
| NCT02873312 |
Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial |
https://ClinicalTrials.gov/show/NCT02873312 |
Recruiting |
Bioness Inc |
2021-07-30 |
| NCT03390790 |
Lidocaine for Pain After Urodynamic Testing |
https://ClinicalTrials.gov/show/NCT03390790 |
Completed |
Atlantic Health System |
2019-03-29 |
| NCT01192568 |
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
https://ClinicalTrials.gov/show/NCT01192568 |
Recruiting |
Allergan |
2021-04-27 |
| NCT02536976 |
Mirabegron in Parkinson Disease and Impaired Cognition |
https://ClinicalTrials.gov/show/NCT02536976 |
Completed |
HealthPartners Institute |
2018-08-01 |
| NCT02526979 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT02526979 |
Completed |
Astellas Pharma Inc |
2016-09-30 |
| NCT02524769 |
The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides |
https://ClinicalTrials.gov/show/NCT02524769 |
Completed |
Loyola University |
2016-11-30 |
| NCT02511717 |
A Trial of Transcutaneous Nerve Stimulation for OAB |
https://ClinicalTrials.gov/show/NCT02511717 |
Completed |
Lawson Health Research Institute |
2019-03-01 |
| NCT02501928 |
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. |
https://ClinicalTrials.gov/show/NCT02501928 |
Completed |
Pfizer |
2020-03-04 |
| NCT02495389 |
Mirabegron and Urinary Urgency Incontinence |
https://ClinicalTrials.gov/show/NCT02495389 |
Recruiting |
Loyola University |
2020-07-31 |
| NCT02494349 |
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. |
https://ClinicalTrials.gov/show/NCT02494349 |
Completed |
Jeil Pharmaceutical Co., Ltd. |
2015-11-30 |
| NCT02476175 |
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02476175 |
Completed |
CHU de Quebec-Universite Laval |
2016-04-30 |
| NCT02468830 |
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02468830 |
Completed |
CHU de Quebec-Universite Laval |
2016-01-31 |
| NCT02468375 |
Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. |
https://ClinicalTrials.gov/show/NCT02468375 |
Completed |
Samsung Medical Center |
2017-10-31 |
| NCT02462837 |
Myrbetriqâ„¢ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement |
https://ClinicalTrials.gov/show/NCT02462837 |
Completed |
Southern Illinois University |
2019-01-30 |
| NCT02447367 |
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers |
https://ClinicalTrials.gov/show/NCT02447367 |
Completed |
Jeil Pharmaceutical Co., Ltd. |
2015-09-30 |
| NCT02396160 |
The Effect of Uroxâ„¢ in the Treatment of Overactive Bladder and Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT02396160 |
Completed |
The University of Queensland |
2014-12-31 |
| NCT02377765 |
Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement. |
https://ClinicalTrials.gov/show/NCT02377765 |
Completed |
Liverpool Women’s NHS Foundation Trust |
2016-10-31 |
| NCT02327936 |
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children |
https://ClinicalTrials.gov/show/NCT02327936 |
Completed |
CHU de Quebec-Universite Laval |
2018-03-31 |
| NCT02320201 |
Foot Neuromodulation for Overactive Bladder in Children |
https://ClinicalTrials.gov/show/NCT02320201 |
Enrolling by invitation |
University of Pittsburgh |
2020-09-30 |
| NCT02315950 |
The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02315950 |
Recruiting |
Cedars-Sinai Medical Center |
2025-12-31 |
| NCT02299544 |
BlueWind Medical System for the Treatment of Patients With OAB |
https://ClinicalTrials.gov/show/NCT02299544 |
Completed |
BlueWind Medical |
2018-08-31 |
| NCT02298660 |
Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI |
https://ClinicalTrials.gov/show/NCT02298660 |
Completed |
Rick Hansen Institute |
2017-10-17 |
| NCT02294396 |
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. |
https://ClinicalTrials.gov/show/NCT02294396 |
Completed |
Astellas Pharma Inc |
2016-09-07 |
| NCT02271607 |
The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT02271607 |
Completed |
Korean Medicine Hospital of Pusan National University |
2015-12-31 |
| NCT02251054 |
Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02251054 |
Completed |
Miami VA Healthcare System |
2013-07-31 |
| NCT02240459 |
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment |
https://ClinicalTrials.gov/show/NCT02240459 |
Completed |
University of Alberta |
2020-01-31 |
| NCT02216214 |
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT02216214 |
Completed |
Astellas Pharma Inc |
2017-11-29 |
| NCT02211846 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02211846 |
Completed |
Astellas Pharma Inc |
2015-09-21 |
| NCT02202031 |
Controlling Urgency Through Relaxation Exercises |
https://ClinicalTrials.gov/show/NCT02202031 |
Completed |
University of California, San Francisco |
2017-12-31 |
| NCT02197533 |
Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions |
https://ClinicalTrials.gov/show/NCT02197533 |
Completed |
St. Michael’s Hospital, Toronto |
2018-01-31 |
| NCT02180997 |
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin |
https://ClinicalTrials.gov/show/NCT02180997 |
Completed |
Jeil Pharmaceutical Co., Ltd. |
2015-03-31 |
| NCT02180048 |
“The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women” |
https://ClinicalTrials.gov/show/NCT02180048 |
Completed |
Loma Linda University |
2018-09-20 |
| NCT02143570 |
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women |
https://ClinicalTrials.gov/show/NCT02143570 |
Completed |
Universidad de Valparaiso |
2016-04-30 |
| NCT02138747 |
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT02138747 |
Completed |
Astellas Pharma Inc |
2015-10-29 |
| NCT02135341 |
Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility |
https://ClinicalTrials.gov/show/NCT02135341 |
Completed |
Buddhist Tzu Chi General Hospital |
2016-12-31 |
| NCT02107820 |
Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders |
https://ClinicalTrials.gov/show/NCT02107820 |
Completed |
University Hospital Plymouth NHS Trust |
2019-03-31 |
| NCT02097121 |
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) |
https://ClinicalTrials.gov/show/NCT02097121 |
Recruiting |
Allergan |
2021-01-15 |
| NCT02092181 |
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson’s Disease (MAESTRO) |
https://ClinicalTrials.gov/show/NCT02092181 |
Completed |
Burdick, Daniel, M.D. |
2018-07-01 |
| NCT01314872 |
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) |
https://ClinicalTrials.gov/show/NCT01314872 |
Completed |
Merck Sharp & Dohme Corp. |
2012-10-22 |
| NCT01314781 |
Therapy of the Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01314781 |
Completed |
Cantonal Hospital, Frauenfeld |
2014-01-31 |
| NCT01302067 |
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine |
https://ClinicalTrials.gov/show/NCT01302067 |
Completed |
Pfizer |
2012-11-30 |
| NCT01302054 |
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. |
https://ClinicalTrials.gov/show/NCT01302054 |
Completed |
Pfizer |
2012-05-31 |
| NCT01294982 |
Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency |
https://ClinicalTrials.gov/show/NCT01294982 |
Completed |
American Oriental Bioengineering, Inc. |
2011-11-30 |
| NCT01286454 |
This Is A Study Of Bioavailability And Food Effect For Fesoterodine. |
https://ClinicalTrials.gov/show/NCT01286454 |
Completed |
Pfizer |
2011-03-31 |
| NCT02045862 |
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT02045862 |
Completed |
Astellas Pharma Inc |
2016-09-08 |
| NCT02040519 |
Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation |
https://ClinicalTrials.gov/show/NCT02040519 |
Completed |
Maastricht University Medical Center |
2017-02-06 |
| NCT03846895 |
Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) |
https://ClinicalTrials.gov/show/NCT03846895 |
Recruiting |
National and Kapodistrian University of Athens |
2019-09-15 |
| NCT01981954 |
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) |
https://ClinicalTrials.gov/show/NCT01981954 |
Completed |
Astellas Pharma Inc |
2015-12-18 |
| NCT01972841 |
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01972841 |
Completed |
Astellas Pharma Inc |
2015-10-22 |
| NCT01971437 |
Cystoscopy and Cystodistension; Therapeutic and Aetiological Aspect in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01971437 |
Completed |
Medway NHS Foundation Trust |
2016-03-31 |
| NCT01945489 |
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01945489 |
Completed |
Allergan |
2016-05-24 |
| NCT01925456 |
Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01925456 |
Completed |
University of Pennsylvania |
2013-12-31 |
| NCT01922115 |
The Effect of Anticholinergics on Cognitive Function in the Elderly |
https://ClinicalTrials.gov/show/NCT01922115 |
Completed |
University of North Carolina, Chapel Hill |
2015-06-30 |
| NCT01912885 |
Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01912885 |
Completed |
University of Sao Paulo General Hospital |
2014-08-25 |
| NCT01908829 |
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) |
https://ClinicalTrials.gov/show/NCT01908829 |
Completed |
Astellas Pharma Inc |
2014-11-24 |
| NCT01870037 |
Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer |
https://ClinicalTrials.gov/show/NCT01870037 |
Completed |
Urovant Sciences GmbH |
2017-06-30 |
| NCT01868516 |
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01868516 |
Completed |
Targacept Inc. |
2014-06-30 |
| NCT04423744 |
Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants |
https://ClinicalTrials.gov/show/NCT04423744 |
Recruiting |
Bayer |
2020-10-19 |
| NCT01848366 |
Utilization of the BIOWAVE Device to Treat Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01848366 |
Completed |
William Beaumont Hospitals |
2014-08-31 |
| NCT01837654 |
Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT01837654 |
Completed |
Assaf-Harofeh Medical Center |
2012-08-31 |
| NCT01833663 |
Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women |
https://ClinicalTrials.gov/show/NCT01833663 |
Completed |
Peking Union Medical College Hospital |
2013-10-31 |
| NCT01824420 |
Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01824420 |
Completed |
Buddhist Tzu Chi General Hospital |
2017-02-28 |
| NCT01783392 |
Peripheral Electrical Stimulation for the Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01783392 |
Completed |
Sheffield Teaching Hospitals NHS Foundation Trust |
2014-12-31 |
| NCT01768910 |
Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction |
https://ClinicalTrials.gov/show/NCT01768910 |
Completed |
University of Zurich |
2015-07-17 |
| NCT01747577 |
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) |
https://ClinicalTrials.gov/show/NCT01747577 |
Completed |
Astellas Pharma Inc |
2013-10-31 |
| NCT01745094 |
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT01745094 |
Completed |
Astellas Pharma Inc |
2013-07-23 |
| NCT01737684 |
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) |
https://ClinicalTrials.gov/show/NCT01737684 |
Completed |
Merck Sharp & Dohme Corp. |
2013-06-14 |
| NCT01729819 |
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women |
https://ClinicalTrials.gov/show/NCT01729819 |
Completed |
Ferring Pharmaceuticals |
2014-11-30 |
| NCT01698138 |
Prevention of Bladder Dysfunction in Acute Spinal Cord Injury |
https://ClinicalTrials.gov/show/NCT01698138 |
Active, not recruiting |
Oslo University Hospital |
2018-12-31 |
| NCT01672190 |
Lessening Incontinence by Learning Yoga |
https://ClinicalTrials.gov/show/NCT01672190 |
Completed |
University of California, San Francisco |
2012-12-31 |
| NCT01661166 |
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy |
https://ClinicalTrials.gov/show/NCT01661166 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2013-04-15 |
| NCT01657409 |
Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01657409 |
Completed |
Buddhist Tzu Chi General Hospital |
2014-06-30 |
| NCT01655069 |
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 |
https://ClinicalTrials.gov/show/NCT01655069 |
Completed |
Astellas Pharma Inc |
2014-10-08 |
| NCT01318837 |
A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment |
https://ClinicalTrials.gov/show/NCT01318837 |
Completed |
Astellas Pharma Inc |
2011-09-30 |
| NCT01642277 |
Bacterial Genomic Sequencing in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01642277 |
Completed |
Loyola University |
2014-07-31 |
| NCT01638000 |
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. |
https://ClinicalTrials.gov/show/NCT01638000 |
Completed |
Astellas Pharma Inc |
2013-04-24 |
| NCT01604928 |
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01604928 |
Completed |
Astellas Pharma Inc |
2005-01-31 |
| NCT01578304 |
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01578304 |
Completed |
LG Life Sciences |
2011-10-31 |
| NCT01566760 |
A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01566760 |
Completed |
Pfizer |
2012-07-31 |
| NCT01565707 |
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug |
https://ClinicalTrials.gov/show/NCT01565707 |
Completed |
Astellas Pharma Inc |
2013-12-31 |
| NCT01565694 |
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT01565694 |
Completed |
Astellas Pharma Inc |
2016-04-28 |
| NCT01539707 |
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01539707 |
Completed |
Astellas Pharma Inc |
2012-08-13 |
| NCT01533597 |
The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT01533597 |
Completed |
Soonchunhyang University Hospital |
2013-12-31 |
| NCT01530620 |
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT01530620 |
Completed |
APOGEPHA Arzneimittel GmbH |
2005-06-30 |
| NCT01521767 |
Pharmacokinetics and Relative Bioavailability Study |
https://ClinicalTrials.gov/show/NCT01521767 |
Completed |
Pfizer |
2011-11-30 |
| NCT01515722 |
Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01515722 |
Completed |
Samsung Medical Center |
2011-12-31 |
| NCT01512004 |
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01512004 |
Completed |
Lee’s Pharmaceutical Limited |
2010-01-31 |
| NCT01503580 |
Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01503580 |
Completed |
National Taiwan University Hospital |
2010-07-31 |
| NCT01502956 |
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA) |
https://ClinicalTrials.gov/show/NCT01502956 |
Completed |
NICHD Pelvic Floor Disorders Network |
2016-07-31 |
| NCT01499069 |
Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT01499069 |
Completed |
Samsung Medical Center |
2015-11-30 |
| NCT01486706 |
Efficacy and Safety of Gabapentin in Treating Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01486706 |
Completed |
St. Luke’s Medical Center, Philippines |
2014-10-31 |
| NCT01458197 |
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT01458197 |
Completed |
Kwang Dong Pharmaceutical co., ltd. |
2012-08-31 |
| NCT01381120 |
Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms |
https://ClinicalTrials.gov/show/NCT01381120 |
Completed |
Barrie Urology Associates |
2012-06-30 |
| NCT01369485 |
Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01369485 |
Completed |
Ethicon Endo-Surgery |
2013-01-31 |
| NCT01367886 |
Comparative Urine Proteomic Studies of Overactive Bladder in Humans |
https://ClinicalTrials.gov/show/NCT01367886 |
Completed |
Washington University School of Medicine |
2011-09-30 |
| NCT01340027 |
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01340027 |
Completed |
Astellas Pharma Inc |
2012-06-28 |
| NCT01960270 |
Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT01960270 |
Completed |
University Hospital, Rouen |
2018-05-02 |
| NCT04369404 |
Impact of Decision Aids in Urogynecology |
https://ClinicalTrials.gov/show/NCT04369404 |
Completed |
Massachusetts General Hospital |
2019-06-01 |
| NCT04364438 |
Effectiveness of EMS and TENS in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04364438 |
Recruiting |
Isra University |
2021-04-30 |
| NCT04305743 |
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A |
https://ClinicalTrials.gov/show/NCT04305743 |
Recruiting |
University of South Florida |
2020-08-01 |
| NCT04270526 |
Minimizing Pain During Office Intradetrussor Botox Injection |
https://ClinicalTrials.gov/show/NCT04270526 |
Recruiting |
Boston Urogynecology Associates |
2021-01-31 |
| NCT04256876 |
TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) |
https://ClinicalTrials.gov/show/NCT04256876 |
Recruiting |
University Hospital, Ghent |
2020-12-31 |
| NCT04232696 |
Neuspera’s Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04232696 |
Recruiting |
Neuspera Medical, Inc. |
2022-07-31 |
| NCT04211831 |
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT04211831 |
Recruiting |
Urovant Sciences GmbH |
2021-06-30 |
| NCT04197466 |
Comparison of Different Treatments for Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT04197466 |
Recruiting |
Ankara Yildirim Beyazıt University |
2020-11-10 |
| NCT04186442 |
Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04186442 |
Recruiting |
Hugel |
2020-06-01 |
| NCT04120545 |
Effectiveness of Microcurrents Therapy in Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT04120545 |
Recruiting |
University of Las Palmas de Gran Canaria |
2020-06-04 |
| NCT04115228 |
Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS) |
https://ClinicalTrials.gov/show/NCT04115228 |
Recruiting |
Nine Continents Medical, Inc. |
2020-09-30 |
| NCT04113941 |
Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04113941 |
Recruiting |
Medy-Tox |
2020-02-29 |
| NCT04103450 |
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
https://ClinicalTrials.gov/show/NCT04103450 |
Enrolling by invitation |
Urovant Sciences GmbH |
2021-07-31 |
| NCT04068025 |
Information, Motivation, Behavioral Skills Model on Urinary Incontinence and Quality of Life in Men |
https://ClinicalTrials.gov/show/NCT04068025 |
Completed |
Ankara Yildirim Beyazıt University |
2018-08-01 |
| NCT04059133 |
The Effect of Low Intensity Extracorporeal Low Energy Shock Wave Therapy on Stress Urinary Incontinence and Overactivity Bladder |
https://ClinicalTrials.gov/show/NCT04059133 |
Recruiting |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2020-07-31 |
| NCT04031014 |
High Intensity Focused Electromagnetic Field Device for Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT04031014 |
Recruiting |
Boston Urogynecology Associates |
2020-07-31 |
| NCT04023253 |
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin |
https://ClinicalTrials.gov/show/NCT04023253 |
Recruiting |
Far Eastern Memorial Hospital |
2022-12-31 |
| NCT04020510 |
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04020510 |
Recruiting |
Walter Reed National Military Medical Center |
2021-07-01 |
| NCT04001426 |
Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device |
https://ClinicalTrials.gov/show/NCT04001426 |
Active, not recruiting |
FemPulse Corporation |
2019-12-31 |
| NCT03946124 |
Fall Prevention in Older Adults With OAB |
https://ClinicalTrials.gov/show/NCT03946124 |
Completed |
University of Pennsylvania |
2017-07-19 |
| NCT03904407 |
Optimizing Overactive Bladder Treatment |
https://ClinicalTrials.gov/show/NCT03904407 |
Completed |
University of North Carolina, Chapel Hill |
2020-05-01 |
| NCT03902080 |
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) |
https://ClinicalTrials.gov/show/NCT03902080 |
Recruiting |
Urovant Sciences GmbH |
2020-11-30 |
| NCT03874780 |
Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03874780 |
Completed |
Vensica Medical Ltd. |
2019-03-31 |
| NCT03829137 |
The Clinical Effects of Laser Acupuncture Therapy for OAB Women. |
https://ClinicalTrials.gov/show/NCT03829137 |
Recruiting |
Chang Gung Memorial Hospital |
2022-04-05 |
| NCT03817931 |
Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03817931 |
Recruiting |
Baylor Research Institute |
2020-05-01 |
| NCT03817203 |
Effects of Kinesio Taping Application in Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03817203 |
Recruiting |
Ataturk Training and Research Hospital |
2019-06-30 |
| NCT03784170 |
FemPulse Therapy for Overactive Bladder in Women |
https://ClinicalTrials.gov/show/NCT03784170 |
Active, not recruiting |
FemPulse Corporation |
2019-12-31 |
| NCT03755089 |
Oral vs Intravesical Analgesia for Office Bladder Botox Injections |
https://ClinicalTrials.gov/show/NCT03755089 |
Recruiting |
Women and Infants Hospital of Rhode Island |
2021-03-01 |
| NCT03753750 |
Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03753750 |
Recruiting |
University of Southern California |
2022-01-01 |
| NCT03750604 |
Central Obesity in Cases of OAB |
https://ClinicalTrials.gov/show/NCT03750604 |
Completed |
Mansoura University |
2018-10-30 |
| NCT03727711 |
TPTNS: Home vs Hospital Treatment for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03727711 |
Recruiting |
NHS Greater Glasgow and Clyde |
2019-03-03 |
| NCT03695692 |
Effects of Connective Tissue Massage in Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03695692 |
Recruiting |
Ataturk Training and Research Hospital |
2019-04-30 |
| NCT03662893 |
Behavioural Therapy With Checklist for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03662893 |
Completed |
Ankara Training and Research Hospital |
2017-12-31 |
| NCT03643380 |
Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT03643380 |
Completed |
Neuspera Medical, Inc. |
2017-11-15 |
| NCT03632772 |
Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP |
https://ClinicalTrials.gov/show/NCT03632772 |
Recruiting |
Buddhist Tzu Chi General Hospital |
2019-07-31 |
| NCT03625843 |
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing |
https://ClinicalTrials.gov/show/NCT03625843 |
Completed |
San Antonio Uniformed Services Health Education Consortium |
2017-12-30 |
| NCT03625492 |
Fluids Affecting Bladder Urgency and Lower Urinary Symptoms |
https://ClinicalTrials.gov/show/NCT03625492 |
Completed |
University of Michigan |
2019-09-17 |
| NCT03596671 |
BlueWind RENOVA iStimâ„¢ System for the Treatment of OAB |
https://ClinicalTrials.gov/show/NCT03596671 |
Recruiting |
BlueWind Medical |
2021-02-28 |
| NCT03595215 |
Posterior Tibial Nerve Stimulation’s Effectiveness in UI Frequency in Overactive Patients in Home |
https://ClinicalTrials.gov/show/NCT03595215 |
Completed |
Theranova, L.L.C. |
2019-07-10 |
| NCT03594058 |
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) |
https://ClinicalTrials.gov/show/NCT03594058 |
Completed |
Velicept Therapeutics, Inc. |
2019-04-29 |
| NCT03583372 |
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). |
https://ClinicalTrials.gov/show/NCT03583372 |
Completed |
Urovant Sciences GmbH |
2019-06-13 |
| NCT03575702 |
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT03575702 |
Completed |
R-Pharm |
2017-08-01 |
| NCT03566134 |
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03566134 |
Completed |
Dong-A ST Co., Ltd. |
2019-12-27 |
| NCT03559946 |
Condensed Percutaneous Tibial Nerve Stimulation (PTNS) Protocol |
https://ClinicalTrials.gov/show/NCT03559946 |
Recruiting |
Stony Brook University |
2022-04-30 |
| NCT03558919 |
Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03558919 |
Completed |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2017-12-30 |
| NCT03556891 |
Pivotal Study of eCoin for OAB With UUI |
https://ClinicalTrials.gov/show/NCT03556891 |
Active, not recruiting |
Valencia Technologies Corporation |
2020-04-12 |
| NCT03547518 |
Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation |
https://ClinicalTrials.gov/show/NCT03547518 |
Recruiting |
William Beaumont Hospitals |
2020-05-23 |
| NCT03544554 |
Training and Counseling Program for Overactive Bladder Treatment |
https://ClinicalTrials.gov/show/NCT03544554 |
Completed |
Biruni University |
2016-10-30 |
| NCT03536494 |
Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron |
https://ClinicalTrials.gov/show/NCT03536494 |
Completed |
Catalan Institute of Health |
2017-12-31 |
| NCT03535857 |
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence |
https://ClinicalTrials.gov/show/NCT03535857 |
Recruiting |
University of Pittsburgh |
2021-05-31 |
| NCT03533062 |
Trigonal vs Non Trigonal Botox Injection in OAB. |
https://ClinicalTrials.gov/show/NCT03533062 |
Completed |
Mansoura University |
2016-10-30 |
| NCT03532789 |
Herbal Patch for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03532789 |
Completed |
En Chu Kong Hospital |
2019-10-23 |
| NCT03523091 |
OnabotulinumtoxinA Bladder Injection Study |
https://ClinicalTrials.gov/show/NCT03523091 |
Active, not recruiting |
William Beaumont Hospitals |
2021-05-31 |
| NCT03520166 |
Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain |
https://ClinicalTrials.gov/show/NCT03520166 |
Completed |
Fisioterapia Pélvica Avanzada Madrid, SRL |
2017-06-15 |
| NCT03508921 |
Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection |
https://ClinicalTrials.gov/show/NCT03508921 |
Recruiting |
Vanderbilt University Medical Center |
2020-06-01 |
| NCT03492281 |
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT03492281 |
Completed |
Urovant Sciences GmbH |
2019-01-10 |
| NCT03475706 |
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women |
https://ClinicalTrials.gov/show/NCT03475706 |
Completed |
Velicept Therapeutics, Inc. |
2019-01-24 |
| NCT03468465 |
Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT03468465 |
Active, not recruiting |
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
2019-03-31 |
| NCT01262391 |
Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents |
https://ClinicalTrials.gov/show/NCT01262391 |
Completed |
Astellas Pharma Inc |
2011-08-14 |
| NCT01220726 |
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction |
https://ClinicalTrials.gov/show/NCT01220726 |
Completed |
Weill Medical College of Cornell University |
2011-06-30 |
| NCT01214265 |
A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01214265 |
Completed |
EMKinetics, Inc |
2010-06-30 |
| NCT01194999 |
Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence |
https://ClinicalTrials.gov/show/NCT01194999 |
Completed |
Barrie Urology Associates |
2012-06-30 |
| NCT01187498 |
Behavioral Treatment of Overactive Bladder in Men |
https://ClinicalTrials.gov/show/NCT01187498 |
Completed |
VA Office of Research and Development |
2009-10-31 |
| NCT01187082 |
Grouptraining for Overactive Bladder in Adults |
https://ClinicalTrials.gov/show/NCT01187082 |
Completed |
University of Aarhus |
2013-03-31 |
| NCT01178827 |
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial |
https://ClinicalTrials.gov/show/NCT01178827 |
Completed |
Allergan |
2011-03-31 |
| NCT01175382 |
Combined Behavioral and Drug Treatment of Overactive Bladder in Men |
https://ClinicalTrials.gov/show/NCT01175382 |
Completed |
University of Alabama at Birmingham |
2015-07-31 |
| NCT01167257 |
Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT01167257 |
Completed |
Buddhist Tzu Chi General Hospital |
2013-12-31 |
| NCT01166438 |
Anticholinergic vs. Botox Comparison Study |
https://ClinicalTrials.gov/show/NCT01166438 |
Completed |
NICHD Pelvic Floor Disorders Network |
2012-05-31 |
| NCT01164280 |
Effect of Pulse Rate Changes on Clinical Outcome |
https://ClinicalTrials.gov/show/NCT01164280 |
Completed |
Maastricht University Medical Center |
2009-12-31 |
| NCT01157377 |
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT01157377 |
Completed |
Allergan |
2013-02-28 |
| NCT01127126 |
Bryophyllum Versus Placebo for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01127126 |
Completed |
University of Zurich |
2012-01-31 |
| NCT01125722 |
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT01125722 |
Completed |
Ethicon Endo-Surgery |
2011-02-28 |
| NCT01093534 |
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT01093534 |
Completed |
Astellas Pharma Inc |
2011-06-30 |
| NCT01091727 |
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT01091727 |
Completed |
Sunnybrook Health Sciences Centre |
2009-04-30 |
| NCT01089751 |
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily |
https://ClinicalTrials.gov/show/NCT01089751 |
Completed |
Allergan |
2012-06-30 |
| NCT01054222 |
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01054222 |
Completed |
Pfizer |
2012-01-31 |
| NCT01043666 |
A Study of YM178 in Subjects With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01043666 |
Completed |
Astellas Pharma Inc |
2011-09-30 |
| NCT01018264 |
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT01018264 |
Completed |
University of South Florida |
2014-08-31 |
| NCT01004315 |
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT01004315 |
Completed |
Kissei Pharmaceutical Co., Ltd. |
NA |
| NCT00966004 |
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00966004 |
Completed |
Astellas Pharma Inc |
2010-02-28 |
| NCT00943904 |
Comparison of Motor and Sensory Response With Interstim Stimulation |
https://ClinicalTrials.gov/show/NCT00943904 |
Completed |
University of California, Irvine |
2012-02-29 |
| NCT00932022 |
Trospium Chloride XR in Obese Female Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00932022 |
Completed |
Allergan |
2011-12-31 |
| NCT00928395 |
Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00928395 |
Completed |
Uroplasty, Inc |
2012-09-30 |
| NCT00928070 |
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00928070 |
Completed |
Pfizer |
2011-09-30 |
| NCT00922506 |
Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) |
https://ClinicalTrials.gov/show/NCT00922506 |
Completed |
Samsung Medical Center |
2014-05-31 |
| NCT00915525 |
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT00915525 |
Completed |
Allergan |
2014-08-05 |
| NCT00914667 |
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00914667 |
Completed |
Pfizer |
2009-08-31 |
| NCT00912964 |
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00912964 |
Completed |
Astellas Pharma Inc |
2010-04-27 |
| NCT00912314 |
Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00912314 |
Completed |
University of California, San Diego |
2010-06-30 |
| NCT00911937 |
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency |
https://ClinicalTrials.gov/show/NCT00911937 |
Completed |
Pfizer |
2011-09-30 |
| NCT00911235 |
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00911235 |
Completed |
Pfizer |
2009-07-31 |
| NCT00910845 |
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT00910845 |
Completed |
Allergan |
2011-07-31 |
| NCT00910520 |
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT00910520 |
Completed |
Allergan |
2011-08-31 |
| NCT00909428 |
Validation of a Real-time Urodynamic Measure of Urinary Urgency |
https://ClinicalTrials.gov/show/NCT00909428 |
Completed |
Loyola University |
2008-07-31 |
| NCT00903045 |
Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00903045 |
Completed |
Samsung Medical Center |
2006-08-31 |
| NCT00902681 |
A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00902681 |
Completed |
Pfizer |
2009-08-31 |
| NCT00902421 |
Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT00902421 |
Completed |
Samsung Medical Center |
2009-07-31 |
| NCT00902187 |
A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00902187 |
Completed |
Pfizer |
2009-06-30 |
| NCT00892450 |
Anticholinergic Therapy for Overactive Bladder in Parkinson’s Disease |
https://ClinicalTrials.gov/show/NCT00892450 |
Completed |
VA Office of Research and Development |
2014-09-30 |
| NCT00884104 |
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks |
https://ClinicalTrials.gov/show/NCT00884104 |
Completed |
Samsung Medical Center |
2010-12-31 |
| NCT00883818 |
Microorganism in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT00883818 |
Completed |
Samsung Medical Center |
2007-12-31 |
| NCT00876447 |
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00876447 |
Completed |
Allergan |
2013-06-12 |
| NCT00876421 |
Study of ONO-8539 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00876421 |
Completed |
Ono Pharmaceutical Co. Ltd |
2010-04-30 |
| NCT00863551 |
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial |
https://ClinicalTrials.gov/show/NCT00863551 |
Completed |
Allergan |
2009-08-31 |
| NCT00862745 |
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) |
https://ClinicalTrials.gov/show/NCT00862745 |
Completed |
University of California, San Francisco |
2010-05-31 |
| NCT00857896 |
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years |
https://ClinicalTrials.gov/show/NCT00857896 |
Completed |
Pfizer |
2010-12-31 |
| NCT00856570 |
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00856570 |
Completed |
Astellas Pharma Inc |
2008-12-31 |
| NCT00852696 |
Over Active Bladder Patients Having Sling Surgery |
https://ClinicalTrials.gov/show/NCT00852696 |
Completed |
The Cleveland Clinic |
2009-07-31 |
| NCT00840645 |
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT00840645 |
Completed |
Astellas Pharma Inc |
2010-03-31 |
| NCT03742206 |
Comparison of Two Forms of Transcutaneous Electrical Stimulation in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT03742206 |
Recruiting |
Hospital de Clinicas de Porto Alegre |
2019-10-31 |
| NCT01628042 |
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) |
https://ClinicalTrials.gov/show/NCT01628042 |
Completed |
Merck Sharp & Dohme Corp. |
2013-01-25 |
| NCT00814736 |
A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 |
https://ClinicalTrials.gov/show/NCT00814736 |
Completed |
Pfizer |
2008-09-30 |
| NCT01781117 |
Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia |
https://ClinicalTrials.gov/show/NCT01781117 |
Completed |
Samsung Medical Center |
2016-11-30 |
| NCT01767519 |
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT01767519 |
Completed |
Allergan |
2014-09-30 |
| NCT00806494 |
UK Study Assessing Flexible Dose Fesoterodine in Adults |
https://ClinicalTrials.gov/show/NCT00806494 |
Completed |
Pfizer |
2010-01-31 |
| NCT00802373 |
Solifenacin Succinate Versus Tolterodine 4mg Once Daily |
https://ClinicalTrials.gov/show/NCT00802373 |
Completed |
Astellas Pharma Inc |
2004-10-31 |
| NCT00801944 |
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms |
https://ClinicalTrials.gov/show/NCT00801944 |
Completed |
Astellas Pharma Inc |
2005-10-31 |
| NCT04450511 |
Pelvic Floor Magnetic Stimulation in Women With Idiopathic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT04450511 |
Recruiting |
Pamukkale University |
2021-09-30 |
| NCT02857816 |
PRospective Study to Evaluate EffectivenesS With the NUROâ„¢ PErcutaneous Tibial Neuromodulation System in Patients With OAB |
https://ClinicalTrials.gov/show/NCT02857816 |
Completed |
MedtronicNeuro |
2017-11-21 |
| NCT03250650 |
Physiotherapy in Overactive Bladder: Electrical Stimulation Treatment |
https://ClinicalTrials.gov/show/NCT03250650 |
Completed |
University of Sao Paulo General Hospital |
2018-04-30 |
| NCT02485067 |
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB |
https://ClinicalTrials.gov/show/NCT02485067 |
Completed |
SK Chemicals Co., Ltd. |
2016-07-31 |
| NCT03952299 |
Oxybutynin for Post-surgical Bladder Pain and Urgency |
https://ClinicalTrials.gov/show/NCT03952299 |
Recruiting |
University of California, Davis |
2025-12-31 |
| NCT03874637 |
FemPulse Therapy First-in-Human Experience |
https://ClinicalTrials.gov/show/NCT03874637 |
Completed |
FemPulse Corporation |
2017-05-17 |
| NCT03758235 |
Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin |
https://ClinicalTrials.gov/show/NCT03758235 |
Active, not recruiting |
University Of Perugia |
2020-09-01 |
| NCT00793611 |
Hypnotherapy for Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00793611 |
Completed |
University of New Mexico |
2010-01-31 |
| NCT00782769 |
A Safety Extension Study of DR-OXY-301 |
https://ClinicalTrials.gov/show/NCT00782769 |
Completed |
Teva Pharmaceutical Industries |
2010-07-31 |
| NCT00771394 |
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia |
https://ClinicalTrials.gov/show/NCT00771394 |
Completed |
Astellas Pharma Inc |
2010-01-31 |
| NCT00771264 |
Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00771264 |
Completed |
Uroplasty, Inc |
2009-06-30 |
| NCT00768521 |
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) |
https://ClinicalTrials.gov/show/NCT00768521 |
Completed |
Merck Sharp & Dohme Corp. |
2009-01-19 |
| NCT00754260 |
Caffeine Reduction and Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00754260 |
Active, not recruiting |
University of New Mexico |
2020-03-31 |
| NCT00746681 |
Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00746681 |
Completed |
Pfizer |
NA |
| NCT00742833 |
A Phase II Study of KUC-7483 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00742833 |
Completed |
Kissei Pharmaceutical Co., Ltd. |
NA |
| NCT00730535 |
Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients |
https://ClinicalTrials.gov/show/NCT00730535 |
Completed |
Samsung Medical Center |
2009-07-31 |
| NCT00706407 |
Uro-NIRS Clinical Study |
https://ClinicalTrials.gov/show/NCT00706407 |
Completed |
Weill Medical College of Cornell University |
2010-05-31 |
| NCT00699049 |
A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00699049 |
Completed |
Samsung Medical Center |
2010-03-31 |
| NCT00689104 |
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00689104 |
Completed |
Astellas Pharma Inc |
2009-03-24 |
| NCT00688688 |
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00688688 |
Completed |
Astellas Pharma Inc |
2010-05-06 |
| NCT00685113 |
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00685113 |
Completed |
Teva Pharmaceutical Industries |
2010-03-31 |
| NCT00678795 |
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00678795 |
Completed |
GW Pharmaceuticals Ltd. |
2005-10-31 |
| NCT00662909 |
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00662909 |
Completed |
Astellas Pharma Inc |
2009-04-22 |
| NCT00658684 |
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00658684 |
Completed |
Pfizer |
2009-08-31 |
| NCT00648310 |
Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT00648310 |
Completed |
Università degli Studi dell’Insubria |
NA |
| NCT00646880 |
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring |
https://ClinicalTrials.gov/show/NCT00646880 |
Completed |
Pfizer |
NA |
| NCT00645281 |
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00645281 |
Completed |
Pfizer |
NA |
| NCT00800462 |
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity |
https://ClinicalTrials.gov/show/NCT00800462 |
Completed |
Toronto Rehabilitation Institute |
2012-06-30 |
| NCT00613327 |
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants |
https://ClinicalTrials.gov/show/NCT00613327 |
Completed |
Janssen Korea, Ltd., Korea |
2008-06-30 |
| NCT00611026 |
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00611026 |
Completed |
Pfizer |
2009-10-31 |
| NCT00603343 |
Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence |
https://ClinicalTrials.gov/show/NCT00603343 |
Completed |
APOGEPHA Arzneimittel GmbH |
2006-09-30 |
| NCT00583219 |
Botulin-A Toxin Instillations and Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00583219 |
Completed |
Mayo Clinic |
2008-05-31 |
| NCT00573508 |
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life |
https://ClinicalTrials.gov/show/NCT00573508 |
Completed |
Astellas Pharma Inc |
2008-07-31 |
| NCT00564226 |
SSR240600C Treatment in Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00564226 |
Completed |
Sanofi |
2009-02-28 |
| NCT00561951 |
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00561951 |
Completed |
Pfizer |
2009-01-31 |
| NCT00553657 |
The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00553657 |
Completed |
GlaxoSmithKline |
2008-01-31 |
| NCT00547378 |
InSite for Over Active Bladder |
https://ClinicalTrials.gov/show/NCT00547378 |
Completed |
MedtronicNeuro |
2016-08-31 |
| NCT00546637 |
Fesoterodine “add-on” Male Overactive Bladder Study |
https://ClinicalTrials.gov/show/NCT00546637 |
Completed |
Pfizer |
2009-02-28 |
| NCT00536484 |
Fesoterodine Flexible Dose Study |
https://ClinicalTrials.gov/show/NCT00536484 |
Completed |
Pfizer |
2008-03-31 |
| NCT00534521 |
Posterior Tibial Nerve Stimulation vs. Sham |
https://ClinicalTrials.gov/show/NCT00534521 |
Completed |
William Beaumont Hospitals |
NA |
| NCT00527033 |
A Study of YM178 in Patients With Symptomatic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00527033 |
Completed |
Astellas Pharma Inc |
2008-04-30 |
| NCT00512785 |
Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00512785 |
Completed |
Ono Pharmaceutical Co. Ltd |
2009-05-31 |
| NCT00507169 |
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT00507169 |
Completed |
Salvat |
2007-09-30 |
| NCT00501267 |
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00501267 |
Completed |
GlaxoSmithKline |
2007-08-31 |
| NCT00481728 |
Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate. |
https://ClinicalTrials.gov/show/NCT00481728 |
Completed |
Pfizer |
2008-12-31 |
| NCT00479505 |
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00479505 |
Completed |
Pfizer |
2008-06-30 |
| NCT00478881 |
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function |
https://ClinicalTrials.gov/show/NCT00478881 |
Completed |
Bayer |
2008-11-30 |
| NCT00465894 |
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00465894 |
Completed |
University of Alabama at Birmingham |
2010-07-31 |
| NCT00463541 |
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00463541 |
Completed |
Astellas Pharma Inc |
2005-04-30 |
| NCT00461292 |
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00461292 |
Completed |
Allergan |
2010-03-31 |
| NCT00454896 |
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT00454896 |
Completed |
Astellas Pharma Inc |
2005-09-30 |
| NCT00454740 |
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00454740 |
Completed |
Astellas Pharma Inc |
2005-08-31 |
| NCT00448175 |
Overactive Bladder Innovative Therapy Trial (OrBIT) |
https://ClinicalTrials.gov/show/NCT00448175 |
Completed |
Uroplasty, Inc |
2008-10-31 |
| NCT00444925 |
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB) |
https://ClinicalTrials.gov/show/NCT00444925 |
Completed |
Pfizer |
2008-07-31 |
| NCT00431041 |
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) |
https://ClinicalTrials.gov/show/NCT00431041 |
Completed |
Astellas Pharma Inc |
2008-02-29 |
| NCT00427596 |
A Two-Part Study to Determine: Best Medication Formulation and Food Effect |
https://ClinicalTrials.gov/show/NCT00427596 |
Completed |
GlaxoSmithKline |
2007-08-31 |
| NCT00425100 |
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT00425100 |
Completed |
Pfizer |
2007-10-31 |
| NCT00409539 |
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) |
https://ClinicalTrials.gov/show/NCT00409539 |
Completed |
Sunovion |
2008-06-30 |
| NCT00979472 |
Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency |
https://ClinicalTrials.gov/show/NCT00979472 |
Completed |
Asan Medical Center |
2010-06-30 |
| NCT00368706 |
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients |
https://ClinicalTrials.gov/show/NCT00368706 |
Completed |
Astellas Pharma Inc |
2008-03-31 |
| NCT00366002 |
Patient’s Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00366002 |
Completed |
Novartis |
NA |
| NCT00350636 |
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo |
https://ClinicalTrials.gov/show/NCT00350636 |
Completed |
Watson Pharmaceuticals |
2007-05-31 |
| NCT00343486 |
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms |
https://ClinicalTrials.gov/show/NCT00343486 |
Completed |
GlaxoSmithKline |
NA |
| NCT00337558 |
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) |
https://ClinicalTrials.gov/show/NCT00337558 |
Completed |
Astellas Pharma Inc |
2007-05-31 |
| NCT00337090 |
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) |
https://ClinicalTrials.gov/show/NCT00337090 |
Completed |
Astellas Pharma Inc |
2007-03-31 |
| NCT00321477 |
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00321477 |
Completed |
GlaxoSmithKline |
2007-02-28 |
| NCT00311376 |
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00311376 |
Completed |
Allergan |
2010-05-31 |
| NCT00293839 |
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00293839 |
Completed |
Alza Corporation, DE, USA |
NA |
| NCT00290563 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00290563 |
Completed |
Merck Sharp & Dohme Corp. |
2007-08-31 |
| NCT00282932 |
Detrol LA In Men With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00282932 |
Completed |
Pfizer |
2007-05-01 |
| NCT00282490 |
Surface Nerve Stimulation Treatment for OAB in Children |
https://ClinicalTrials.gov/show/NCT00282490 |
Completed |
University of Aarhus |
2008-03-31 |
| NCT00231790 |
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) |
https://ClinicalTrials.gov/show/NCT00231790 |
Completed |
Merck Sharp & Dohme Corp. |
2006-09-30 |
| NCT00231491 |
Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00231491 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2010-04-30 |
| NCT00230789 |
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication. |
https://ClinicalTrials.gov/show/NCT00230789 |
Completed |
Pfizer |
2006-12-31 |
| NCT00224146 |
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00224146 |
Completed |
Watson Pharmaceuticals |
2005-05-31 |
| NCT00220402 |
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT00220402 |
Completed |
Pfizer |
2007-07-31 |
| NCT00220389 |
Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase |
https://ClinicalTrials.gov/show/NCT00220389 |
Completed |
Pfizer |
2007-06-30 |
| NCT00220376 |
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT00220376 |
Completed |
Pfizer |
2007-07-31 |
| NCT00220363 |
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT00220363 |
Completed |
Pfizer |
2005-02-28 |
| NCT00212732 |
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan |
https://ClinicalTrials.gov/show/NCT00212732 |
Completed |
Ono Pharmaceutical Co. Ltd |
2006-04-30 |
| NCT00212706 |
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan |
https://ClinicalTrials.gov/show/NCT00212706 |
Completed |
Ono Pharmaceutical Co. Ltd |
2002-11-30 |
| NCT00196404 |
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00196404 |
Completed |
Teva Pharmaceutical Industries |
2006-12-31 |
| NCT00189800 |
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00189800 |
Completed |
Astellas Pharma Inc |
NA |
| NCT00174798 |
MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence. |
https://ClinicalTrials.gov/show/NCT00174798 |
Completed |
Sanofi |
2006-05-31 |
| NCT00171184 |
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00171184 |
Completed |
Novartis |
NA |
| NCT00171145 |
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00171145 |
Completed |
Novartis |
NA |
| NCT00170755 |
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00170755 |
Completed |
Novartis |
NA |
| NCT00168454 |
A Research Study for Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00168454 |
Completed |
Allergan |
2008-01-31 |
| NCT00143481 |
Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women |
https://ClinicalTrials.gov/show/NCT00143481 |
Completed |
Pfizer |
2006-06-30 |
| NCT00138723 |
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome |
https://ClinicalTrials.gov/show/NCT00138723 |
Completed |
Pfizer |
2005-02-28 |
| NCT00137397 |
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00137397 |
Completed |
Pfizer |
NA |
| NCT00131573 |
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome |
https://ClinicalTrials.gov/show/NCT00131573 |
Completed |
Boston Scientific Corporation |
2008-03-31 |
| NCT00127270 |
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00127270 |
Completed |
Novartis |
NA |
| NCT00798434 |
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. |
https://ClinicalTrials.gov/show/NCT00798434 |
Completed |
Pfizer |
2010-09-30 |
| NCT00836381 |
Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00836381 |
Completed |
Samsung Medical Center |
2012-01-31 |
| NCT00795925 |
Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder |
https://ClinicalTrials.gov/show/NCT00795925 |
Completed |
APOGEPHA Arzneimittel GmbH |
NA |
| NCT00238680 |
Programmable Timer in the Bladder Rehabilitation Treatment of OAB |
https://ClinicalTrials.gov/show/NCT00238680 |
Completed |
University of Aarhus |
2006-09-30 |